CGT Catapult annual review shows sector’s impact on economy and patient access

Early treatment with vamorolone shows sustained efficacy and improved safety profile

Deal strengthens CNS portfolio and ensures continuity of access for MS patients

Three-year trial results reveal long-term improvements in pain and lesion resolution

New self-loading reagents offer unmatched flexibility for immunologists

First-in-class mast cell selective c-Kit inhibitor enters clinical testing in Germany

SBT-77-7101 shows favourable safety and early signs of efficacy in patients with refractory RA

Faster scans and same-day results improve patient experience across community sites

New data support European filing for nonsteroidal topical treatment

Domain Therapeutics has announced the first patients have been dosed in its phase 1/2 DOMISOL clinical trial of […]